Works matching DE "BIOSIMILARS"
Results: 891
FDA Approves Yesintek, Sixth Stelara Biosimilar; Launch Slated for February.
- Published in:
- Healio Gastroenterology, 2025, v. 11, n. 1, p. 24
- Publication type:
- Article
FDA approves first rapid-acting insulin biosimilar product for treatment of diabetes.
- Published in:
- Rhode Island Medical Journal, 2025, v. 108, n. 3, p. 55
- Publication type:
- Article
Impact of Nonmedical Switches From Reference Infliximab to Biosimilars on Disease Control Within a Rheumatology Practice.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 83, doi. 10.1177/87551225241308475
- By:
- Publication type:
- Article
Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 90, doi. 10.1177/87551225241306675
- By:
- Publication type:
- Article
The Role of Outcome Response Rate in Planning Biosimilar Studies Using Different Evaluation Metrics.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 243, doi. 10.3390/ph18020243
- By:
- Publication type:
- Article
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 3, p. 1269, doi. 10.1007/s10067-023-06822-2
- By:
- Publication type:
- Article
Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 8, p. 1999, doi. 10.1007/s10067-023-06540-9
- By:
- Publication type:
- Article
Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Response to: Biosimilars for vasculitis: promise requires validation by quality studies.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Biosimilars for vasculitis: promise requires validation by quality studies.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Preconceived notions about biosimilars—a French experience.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Biosimilars in the Americas: the future by consensus.
- Published in:
- 2019
- By:
- Publication type:
- Editorial
PANLAR consensus statement on biosimilars.
- Published in:
- Clinical Rheumatology, 2019, v. 38, n. 5, p. 1485, doi. 10.1007/s10067-019-04496-3
- By:
- Publication type:
- Article
Comparative Study of the Stability of Eculizumab Biosimilar and the Original Drug under Extreme pH, Oxidative Stress, and UV Irradiation Conditions.
- Published in:
- Pharmaceutical Chemistry Journal, 2021, v. 55, n. 7, p. 732, doi. 10.1007/s11094-021-02485-y
- By:
- Publication type:
- Article
ISSUE HIGHLIGHTS.
- Published in:
- 2018
- Publication type:
- Abstract
Evaluation of Feed Strategy for High Quality Biosimilar IgG Production in CHO Cell Fed-batch Process.
- Published in:
- Acibadem Saglik Bilimleri Dergisi, 2022, v. 13, n. 1, p. 6, doi. 10.31067/acusaglik.934263
- By:
- Publication type:
- Article
Incidence of inflammatory reactions after intravitreal injection of a biosimilar of ranibizumab for the treatment of various retinal vascular conditions.
- Published in:
- Indian Journal of Health Sciences & Biomedical Research KLEU, 2023, v. 16, n. 2, p. 225, doi. 10.4103/kleuhsj.kleuhsj_234_21
- By:
- Publication type:
- Article
Current perspectives on biosimilars.
- Published in:
- Journal of Industrial Microbiology & Biotechnology, 2019, v. 46, n. 9/10, p. 1297, doi. 10.1007/s10295-019-02216-z
- By:
- Publication type:
- Article
FDA Expands Approval of Stelara Biosimilar Selarsdi to Include UC, Crohn's Disease.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 12, p. 27
- Publication type:
- Article
FDA Approves High-Concentration, Citrate-Free Form of Interchangeable Biosimilar Cyltezo.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 6, p. 30
- By:
- Publication type:
- Article
Interchangeable Biosimilars May Cut Costs or Cause ‘Cognitive Dissonance’.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 4, p. 14
- By:
- Publication type:
- Article
VIDEO: ‘We All Need to Be Concerned’ About Consequences of Inequity in Health Care.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 4, p. 9
- By:
- Publication type:
- Article
Benefit of Biosimilar Switching ‘Less Apparent’ to GIs, Patients vs. Third-Party Payers.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 4, p. 7
- By:
- Publication type:
- Article
Biotherapeutics and its applications in microbiology.
- Published in:
- Environment Conservation Journal, 2021, v. 22, p. 63, doi. 10.36953/ECJ.2021.SE.2207
- By:
- Publication type:
- Article
Future of anti-VEGF: biosimilars and biobetters.
- Published in:
- International Journal of Retina & Vitreous, 2022, v. 8, n. 1, p. 1, doi. 10.1186/s40942-021-00343-3
- By:
- Publication type:
- Article
HOW TO MINIMISE INSULIN ERRORS.
- Published in:
- Diabetes & Primary Care, 2022, v. 24, n. 6, p. 181
- By:
- Publication type:
- Article
Slowing, halting and reversing the upward trend in type 2 diabetes.
- Published in:
- Diabetes & Primary Care, 2019, v. 21, n. 5, p. 147
- By:
- Publication type:
- Article
Nanomedicines and off patent follow-on medicines (nanosimilars) EMA regulatory procedures overview.
- Published in:
- Macedonian Pharmaceutical Bulletin / Makedonsko Farmacevtski Bilten, 2023, v. 69, p. 69, doi. 10.33320/maced.pharm.bull.2023.69.03.034
- By:
- Publication type:
- Article
Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars.
- Published in:
- Journal of Market Access & Health Policy, 2023, v. 11, n. 1, p. 1, doi. 10.1080/20016689.2022.2147286
- By:
- Publication type:
- Article
Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
- Published in:
- Journal of Market Access & Health Policy, 2020, v. 8, n. 1, p. 1, doi. 10.1080/20016689.2020.1739509
- By:
- Publication type:
- Article
Tendering and biosimilars: what role for value-added services?
- Published in:
- Journal of Market Access & Health Policy, 2020, v. 8, n. 1, p. 1, doi. 10.1080/20016689.2019.1705120
- By:
- Publication type:
- Article
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/9996193
- By:
- Publication type:
- Article
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/9996193
- By:
- Publication type:
- Article
Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2173, doi. 10.1007/s13555-022-00781-3
- By:
- Publication type:
- Article
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 6, p. 1303, doi. 10.1007/s13555-022-00732-y
- By:
- Publication type:
- Article
Confidence in Biosimilar Drugs is Not Much Improved by Framing Them as the "Gold" Alternative Treatment Option to Bio-originators.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 4, p. 1409, doi. 10.1007/s13555-021-00542-8
- By:
- Publication type:
- Article
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
- Published in:
- Dermatology & Therapy, 2018, v. 8, n. 2, p. 173, doi. 10.1007/s13555-018-0230-9
- By:
- Publication type:
- Article
Rheumatoid Arthritis: Applicability of Ready-to-Use Human Cartilaginous Cells for Screening of Compounds with TNF-Alpha Inhibitory Activity.
- Published in:
- Biomolecules (2218-273X), 2020, v. 10, n. 11, p. 1563, doi. 10.3390/biom10111563
- By:
- Publication type:
- Article
The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.
- Published in:
- Biomolecules (2218-273X), 2019, v. 9, n. 9, p. 410, doi. 10.3390/biom9090410
- By:
- Publication type:
- Article
Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing.
- Published in:
- Biomolecules (2218-273X), 2019, v. 9, n. 2, p. 57, doi. 10.3390/biom9020057
- By:
- Publication type:
- Article
An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift.
- Published in:
- Biomolecules (2218-273X), 2018, v. 8, n. 3, p. 89, doi. 10.3390/biom8030089
- By:
- Publication type:
- Article
Nocebo in Biosimilars and Generics in Neurology: A Systematic Review.
- Published in:
- Frontiers in Pharmacology, 2019, p. 1, doi. 10.3389/fphar.2019.00809
- By:
- Publication type:
- Article
Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00279
- By:
- Publication type:
- Article
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines.
- Published in:
- Frontiers in Pharmacology, 2018, p. N.PAG, doi. 10.3389/fphar.2018.01079
- By:
- Publication type:
- Article
Immunogenicity: Clouding the Future of Intravitreal Therapy.
- Published in:
- Ocular Immunology & Inflammation, 2023, v. 31, n. 9, p. 1746, doi. 10.1080/09273948.2022.2139273
- By:
- Publication type:
- Article
What Went Wrong: How Formularies, Contracts, and Rebates Created a Headwind for Biosimilars.
- Published in:
- American Journal of Pharmacy Benefits, 2024, p. 4
- By:
- Publication type:
- Article
Learning to Stay Ahead of Payer Policy Changes in Biosimilar Coverage Within Oncology Pharmacy Practice.
- Published in:
- American Journal of Pharmacy Benefits, 2022, p. 3
- By:
- Publication type:
- Article
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
- Published in:
- Journal of Gastrointestinal & Liver Diseases, 2022, v. 31, n. 4, p. 411, doi. 10.15403/jgld-4608
- By:
- Publication type:
- Article
Policy Recommendations to Promote Prescription Drug Competition: A Position Paper From the American College of Physicians.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Biosimilars for Management of Crohn Disease.
- Published in:
- 2019
- By:
- Publication type:
- Editorial